Cancer-specific algorithms show much better performance than general algorithms for variant functional impact prediction in three benchmark analyses (3D clustering, p = 1.6 × 10−4; TP53 mutations, p = 0.08; and in vitro assays, p = 7 × 10−4). This evidence concerns the gene TP53 and cancer.